J
Jafron Biomedical Co Ltd
SZSE:300529
Jafron Biomedical Co Ltd
SZSE:300529
Price:
18.79
CNY
0.43%
Market Cap:
¥15B
Income Statement
Earnings Waterfall
Jafron Biomedical Co Ltd
Jafron Biomedical Co Ltd
Income Statement
Jafron Biomedical Co Ltd
Jafron Biomedical Co Ltd
Currency: CNY
| Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
9
|
13
|
18
|
19
|
36
|
43
|
51
|
62
|
54
|
58
|
62
|
62
|
64
|
62
|
0
|
0
|
|
| Revenue |
509
N/A
|
532
+5%
|
547
+3%
|
537
-2%
|
544
+1%
|
566
+4%
|
612
+8%
|
662
+8%
|
719
+9%
|
777
+8%
|
846
+9%
|
925
+9%
|
1 017
+10%
|
1 105
+9%
|
1 219
+10%
|
1 290
+6%
|
1 432
+11%
|
1 516
+6%
|
1 643
+8%
|
1 776
+8%
|
1 951
+10%
|
2 151
+10%
|
2 269
+6%
|
2 417
+7%
|
2 675
+11%
|
2 794
+4%
|
3 041
+9%
|
2 919
-4%
|
2 491
-15%
|
2 367
-5%
|
1 949
-18%
|
1 952
+0%
|
1 922
-2%
|
2 094
+9%
|
2 406
+15%
|
2 632
+9%
|
2 677
+2%
|
2 481
-7%
|
2 316
-7%
|
2 038
-12%
|
|
| Gross Profit | |||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(79)
|
(93)
|
(93)
|
(91)
|
(87)
|
(104)
|
(113)
|
(123)
|
(114)
|
(136)
|
(149)
|
(158)
|
(155)
|
(186)
|
(199)
|
(206)
|
(197)
|
(232)
|
(253)
|
(273)
|
(288)
|
(351)
|
(370)
|
(406)
|
(402)
|
(467)
|
(524)
|
(514)
|
(440)
|
(477)
|
(414)
|
(419)
|
(385)
|
(466)
|
(518)
|
(550)
|
(520)
|
(502)
|
(491)
|
(457)
|
|
| Gross Profit |
430
N/A
|
440
+2%
|
454
+3%
|
447
-2%
|
456
+2%
|
462
+1%
|
500
+8%
|
539
+8%
|
605
+12%
|
641
+6%
|
698
+9%
|
766
+10%
|
862
+12%
|
919
+7%
|
1 020
+11%
|
1 084
+6%
|
1 234
+14%
|
1 284
+4%
|
1 389
+8%
|
1 503
+8%
|
1 663
+11%
|
1 800
+8%
|
1 899
+5%
|
2 011
+6%
|
2 273
+13%
|
2 327
+2%
|
2 518
+8%
|
2 405
-4%
|
2 051
-15%
|
1 890
-8%
|
1 535
-19%
|
1 533
0%
|
1 537
+0%
|
1 629
+6%
|
1 888
+16%
|
2 082
+10%
|
2 157
+4%
|
1 979
-8%
|
1 825
-8%
|
1 580
-13%
|
|
| Operating Income | |||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(203)
|
(209)
|
(219)
|
(219)
|
(231)
|
(225)
|
(236)
|
(259)
|
(318)
|
(317)
|
(343)
|
(369)
|
(430)
|
(440)
|
(459)
|
(499)
|
(598)
|
(576)
|
(587)
|
(613)
|
(652)
|
(681)
|
(689)
|
(741)
|
(903)
|
(890)
|
(990)
|
(1 016)
|
(1 045)
|
(1 042)
|
(1 070)
|
(1 037)
|
(1 008)
|
(1 006)
|
(1 031)
|
(1 081)
|
(1 121)
|
(1 056)
|
(990)
|
(949)
|
|
| Selling, General & Administrative |
(182)
|
(206)
|
(214)
|
(214)
|
(202)
|
(224)
|
(240)
|
(243)
|
(285)
|
(299)
|
(324)
|
(358)
|
(398)
|
(423)
|
(447)
|
(481)
|
(550)
|
(541)
|
(556)
|
(587)
|
(604)
|
(639)
|
(635)
|
(666)
|
(755)
|
(750)
|
(840)
|
(843)
|
(851)
|
(862)
|
(855)
|
(826)
|
(794)
|
(800)
|
(826)
|
(882)
|
(901)
|
(837)
|
(772)
|
(729)
|
|
| Research & Development |
(17)
|
(4)
|
0
|
0
|
(22)
|
0
|
0
|
0
|
(27)
|
0
|
0
|
(21)
|
(45)
|
(40)
|
(56)
|
(62)
|
(67)
|
(67)
|
(70)
|
(69)
|
(78)
|
(89)
|
(101)
|
(129)
|
(164)
|
(194)
|
(222)
|
(240)
|
(234)
|
(267)
|
(269)
|
(268)
|
(212)
|
(246)
|
(244)
|
(244)
|
(199)
|
(239)
|
(225)
|
(212)
|
|
| Depreciation & Amortization |
(4)
|
(2)
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(10)
|
0
|
0
|
0
|
(13)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(31)
|
0
|
0
|
0
|
(40)
|
0
|
0
|
0
|
(56)
|
0
|
0
|
0
|
(67)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
(0)
|
3
|
(6)
|
(5)
|
(0)
|
(1)
|
3
|
(16)
|
(0)
|
(18)
|
(19)
|
10
|
23
|
23
|
45
|
43
|
32
|
33
|
39
|
43
|
47
|
48
|
46
|
53
|
47
|
53
|
72
|
68
|
81
|
87
|
53
|
57
|
54
|
39
|
39
|
44
|
45
|
20
|
7
|
(7)
|
|
| Operating Income |
227
N/A
|
231
+2%
|
235
+2%
|
228
-3%
|
226
-1%
|
237
+5%
|
263
+11%
|
281
+7%
|
287
+2%
|
324
+13%
|
355
+10%
|
397
+12%
|
432
+9%
|
480
+11%
|
562
+17%
|
585
+4%
|
636
+9%
|
708
+11%
|
802
+13%
|
890
+11%
|
1 011
+14%
|
1 119
+11%
|
1 210
+8%
|
1 270
+5%
|
1 370
+8%
|
1 437
+5%
|
1 528
+6%
|
1 389
-9%
|
1 006
-28%
|
848
-16%
|
466
-45%
|
495
+6%
|
529
+7%
|
623
+18%
|
857
+38%
|
1 001
+17%
|
1 036
+3%
|
923
-11%
|
835
-9%
|
631
-24%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
5
|
6
|
5
|
6
|
8
|
10
|
21
|
23
|
38
|
46
|
46
|
54
|
44
|
44
|
41
|
37
|
44
|
45
|
46
|
45
|
44
|
42
|
46
|
46
|
47
|
39
|
38
|
35
|
29
|
27
|
23
|
28
|
35
|
28
|
22
|
9
|
11
|
10
|
14
|
18
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
(1)
|
0
|
(1)
|
0
|
18
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
1
|
(0)
|
1
|
1
|
1
|
(7)
|
(0)
|
0
|
0
|
(20)
|
3
|
3
|
3
|
(3)
|
0
|
0
|
(2)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
8
|
9
|
11
|
11
|
9
|
9
|
16
|
15
|
(2)
|
6
|
11
|
9
|
(3)
|
(5)
|
(19)
|
(18)
|
(8)
|
(18)
|
(20)
|
(19)
|
(22)
|
(11)
|
(12)
|
(15)
|
(9)
|
(11)
|
(11)
|
(11)
|
(11)
|
(20)
|
(20)
|
(23)
|
(22)
|
(24)
|
(29)
|
(36)
|
(37)
|
(41)
|
(41)
|
(43)
|
|
| Pre-Tax Income |
240
N/A
|
245
+2%
|
250
+2%
|
244
-2%
|
242
-1%
|
257
+6%
|
299
+17%
|
319
+6%
|
340
+7%
|
376
+11%
|
412
+9%
|
460
+12%
|
473
+3%
|
518
+10%
|
584
+13%
|
603
+3%
|
671
+11%
|
735
+9%
|
829
+13%
|
916
+11%
|
1 032
+13%
|
1 150
+11%
|
1 244
+8%
|
1 302
+5%
|
1 407
+8%
|
1 466
+4%
|
1 555
+6%
|
1 415
-9%
|
1 017
-28%
|
855
-16%
|
469
-45%
|
500
+7%
|
521
+4%
|
629
+21%
|
852
+35%
|
977
+15%
|
1 007
+3%
|
892
-11%
|
809
-9%
|
604
-25%
|
|
| Net Income | |||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
(39)
|
(35)
|
(41)
|
(40)
|
(39)
|
(42)
|
(49)
|
(52)
|
(56)
|
(61)
|
(66)
|
(73)
|
(72)
|
(78)
|
(88)
|
(91)
|
(103)
|
(112)
|
(126)
|
(138)
|
(159)
|
(178)
|
(191)
|
(193)
|
(211)
|
(218)
|
(232)
|
(212)
|
(136)
|
(114)
|
(59)
|
(67)
|
(95)
|
(115)
|
(151)
|
(183)
|
(193)
|
(174)
|
(157)
|
(127)
|
|
| Income from Continuing Operations |
200
|
210
|
209
|
204
|
202
|
215
|
251
|
266
|
285
|
315
|
345
|
387
|
401
|
440
|
496
|
512
|
569
|
623
|
703
|
778
|
873
|
972
|
1 053
|
1 109
|
1 196
|
1 247
|
1 323
|
1 203
|
881
|
742
|
410
|
432
|
426
|
514
|
701
|
794
|
814
|
718
|
652
|
477
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
3
|
3
|
3
|
2
|
2
|
2
|
1
|
1
|
1
|
2
|
4
|
9
|
9
|
9
|
7
|
11
|
10
|
10
|
10
|
6
|
6
|
5
|
5
|
|
| Net Income (Common) |
200
N/A
|
210
+5%
|
209
0%
|
204
-2%
|
202
-1%
|
215
+6%
|
251
+17%
|
266
+6%
|
284
+7%
|
315
+11%
|
345
+10%
|
387
+12%
|
402
+4%
|
442
+10%
|
498
+13%
|
514
+3%
|
571
+11%
|
626
+10%
|
706
+13%
|
780
+11%
|
875
+12%
|
974
+11%
|
1 055
+8%
|
1 111
+5%
|
1 197
+8%
|
1 249
+4%
|
1 325
+6%
|
1 207
-9%
|
890
-26%
|
751
-16%
|
419
-44%
|
440
+5%
|
436
-1%
|
525
+20%
|
711
+36%
|
804
+13%
|
820
+2%
|
724
-12%
|
657
-9%
|
482
-27%
|
|
| EPS (Diluted) |
0.29
N/A
|
0.3
+3%
|
0.3
N/A
|
0.26
-13%
|
0.27
+4%
|
0.27
N/A
|
0.33
+22%
|
0.35
+6%
|
0.36
+3%
|
0.39
+8%
|
0.43
+10%
|
0.48
+12%
|
0.51
+6%
|
0.56
+10%
|
0.63
+12%
|
0.65
+3%
|
0.73
+12%
|
0.78
+7%
|
0.88
+13%
|
0.97
+10%
|
1.1
+13%
|
1.21
+10%
|
1.35
+12%
|
1.39
+3%
|
1.49
+7%
|
1.52
+2%
|
1.64
+8%
|
1.49
-9%
|
1.12
-25%
|
0.93
-17%
|
0.51
-45%
|
0.53
+4%
|
0.55
+4%
|
0.64
+16%
|
0.87
+36%
|
0.98
+13%
|
1.05
+7%
|
0.89
-15%
|
0.84
-6%
|
0.61
-27%
|
|
Switch to:
Switch to:
See Also
Discover More
